News >

Nivolumab Alone or With Ipilimumab Provides Durable Benefit in MSI-H/dMMR mCRC

Wayne Kuznar
Published: Tuesday, Jan 23, 2018

Michael J. Overman, MD
Michael J. Overman, MD
Data from the CheckMate-142 study support the use of nivolumab (Opdivo) alone or in combination with ipilimumab (Yervoy) for the treatment of patients with previously treated DNA mismatch repair-deficient (dMMR)/microsatellite instability-high (MSI-H) metastatic colorectal cancer (mCRC), according to 2 analyses presented at the 2018 Gastrointestinal Cancers Symposium.
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: 22nd Annual International Congress on Hematologic Malignancies®: Focus on Leukemias, Lymphomas and MyelomaMay 30, 20192.0
Online Medical Crossfire®: 5th Annual Miami Lung Cancer ConferenceMay 30, 20196.5
Publication Bottom Border
Border Publication
x